CH
IBB icon

Canton Hathaway’s iShares Biotechnology ETF IBB Stock Holding History

Canton Hathaway’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.66M Sell
8,711
-1,250
-13% -$215K 0.32% 40
2026
Q1 		$1.68M Hold
9,961
– – 0.34% 44
2025
Q4 		$1.68M Hold
9,961
– – 0.32% 38
2025
Q3 		$1.44M Hold
9,961
– – 0.28% 47
2025
Q2 		$1.26M Sell
9,961
-4,500
-31% -$552K 0.26% 47
2025
Q1 		$1.85M Buy
14,461
+4,500
+45% +$610K 0.37% 32
2024
Q4 		$1.32M Buy
9,961
+100
+1% +$14.1K 0.33% 39
2024
Q3 		$1.44M Sell
9,861
-190
-2% -$27.5K 0.36% 35
2024
Q2 		$1.38M Hold
10,051
– – 0.38% 37
2024
Q1 		$1.38M Hold
10,051
– – 0.37% 36
2023
Q4 		$1.36M Sell
10,051
-1,200
-11% -$146K 0.41% 31
2023
Q3 		$1.38M Hold
11,251
– – 0.44% 31
2023
Q2 		$1.43M Sell
11,251
-1,600
-12% -$208K 0.45% 32
2023
Q1 		$1.66M Buy
12,851
+8
+0.1% +$1.05K 0.57% 27
2022
Q4 		$1.69M Sell
12,843
-2,130
-14% -$275K 0.59% 25
2022
Q3 		$1.75M Buy
14,973
+435
+3% +$54K 0.64% 25
2022
Q2 		$1.71M Hold
14,538
– – 0.6% 28
2022
Q1 		$1.89M Sell
14,538
-2,588
-15% -$337K 0.53% 32
2021
Q4 		$2.61M Buy
17,126
+210
+1% +$32.5K 0.71% 26
2021
Q3 		$2.73M Buy
16,916
+1,672
+11% +$281K 0.79% 23
2021
Q2 		$2.5M Buy
15,244
+773
+5% +$119K 0.73% 27
2021
Q1 		$2.18M Buy
14,471
+597
+4% +$94.8K 0.7% 26
2020
Q4 		$2.1M Buy
13,874
+6,568
+90% +$939K 0.71% 26
2020
Q3 		$989K Buy
7,306
+4,016
+122% +$545K 0.41% 35
2020
Q2 		$450K Buy
3,290
+418
+15% +$53.3K 0.29% 41
2020
Q1 		$309K Buy
2,872
+625
+28% +$72K 0.22% 48
2019
Q4 		$271K Hold
2,247
– – 0.14% 73
2019
Q3 		$224K Hold
2,247
– – 0.12% 77
2019
Q2 		$245K Buy
2,247
+500
+29% +$53.2K 0.14% 73
2019
Q1 		$195K Hold
1,747
– – 0.11% 74
2018
Q4 		$168K Buy
1,747
+1,192
+215% +$127K 0.11% 66
2018
Q3 		$68K Buy
+555
New +$65.4K 0.04% 89

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $22.8B AUM 28.56% 1-Year Est. Return

Canton Hathaway's IBB Position: Q2 2026 in Review

Canton Hathaway reduced its iShares Biotechnology ETF (IBB) stake by 13% in Q2 2026, selling an estimated $215K and leaving 8,711 shares worth $1.66M. The position accounts for 0.32% of the portfolio, ranked #40.

Canton Hathaway first reported a position in IBB in Q3 2018 and has held it in 32 quarters since. The position peaked at $2.73M in Q3 2021. 956 funds tracked by Wall St. Rank hold IBB as of Q2 2026.

  • Canton Hathaway held 8,711 shares of iShares Biotechnology ETF worth $1.66M as of Q2 2026.
  • Canton Hathaway sold 1,250 iShares Biotechnology ETF shares in Q2 2026, an estimated $215K.
  • iShares Biotechnology ETF made up 0.32% of Canton Hathaway's portfolio in Q2 2026, its #40 holding.
  • Canton Hathaway first reported a position in iShares Biotechnology ETF in Q3 2018 and has held it in 32 quarters since.
  • Canton Hathaway's iShares Biotechnology ETF position peaked at $2.73M in Q3 2021.
  • 956 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.

Based on Canton Hathaway's 13F filing for Q2 2026, filed 6 Aug 2026.